

Effect of anti-tumour necrosis factor alpha (TNF α) therapy on blood vessel health in patients with rheumatoid arthritis

| | | |
|--|---|--|
| Submission date 07/04/2008 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| Registration date 09/05/2008 | Overall study status Completed | <input type="checkbox"/> Protocol |
| Last Edited 02/02/2015 | Condition category Musculoskeletal Diseases | <input type="checkbox"/> Statistical analysis plan |
| | | <input checked="" type="checkbox"/> Results |
| | | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Jill Belch

Contact details

Vascular and Inflammatory Diseases Research Unit
The Institute of Cardiovascular Research
University Division of Medicine and Therapeutics
Ninewells Hospital and Medical School
University of Dundee
Dundee
United Kingdom
DD1 9SY
+44 (0)1382 632457
j.j.f.belch@dundee.ac.uk

Additional identifiers

Protocol serial number

ETADA90 v1

Study information

Scientific Title

Effect of anti-tumour necrosis factor alpha (TNF α) therapy on endothelial function and other surrogate markers of cardiovascular disease in patients with rheumatoid arthritis

Study objectives

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder characterized by a symmetrical erosive polyarthritis with inflammatory multisystemic involvement. Most patients exhibit a chronic fluctuating course of disease that, if left untreated, results in progressive joint destruction, deformity, and disability. The patient with RA has their life span shortened by 15-20%, with 34-40% of excess deaths being due to cardiovascular disease.

Study aim:

To assess the effect of the TNF α blocking drug etanercept and adalimumab on endothelial dysfunction and other surrogate markers of cardiovascular diseases in patients with RA. We hypothesised that the biologic drugs have the potential to improve endothelial dysfunction and other surrogate markers of cardiovascular disease (CVD) in patients with RA. We believe that if etanercept and adalimumab can improve endothelial dysfunction in RA patients they may be able to reduce the cardiovascular morbidity and mortality seen in this group of patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Tayside Committee on Medical Research Ethics. Date of approval: 05/09/2005 (ref: 05/S1401/112)

Study design

Observational open-label single-centre study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

This is an observational study. The drugs are prescribed by the rheumatology team, and this study assesses the impact of those drugs on blood vessel health.

90 RA patients (30 due to be started on methotrexate, 30 due to be started on etanercept and 30 due to be started on adalimumab) will be recruited from rheumatology clinics throughout Tayside. Treatment allocation (etanercept, adalimumab or methotrexate) will be decided by the rheumatologists in the clinic.

The drugs are normally prescribed as:

Etanercept: Subcutaneous injections 25 mg twice a week or 50 mg once a week

Adalimumab: Subcutaneous injections 40 mg every other week

Methotrexate: Orally once a week. Doses range from 7.5 mg a week to 25 mg a week

Surrogate markers of cardiovascular disease will be measured at baseline (before commencement of methotrexate/ etanercept/ adalimumab), 2 months and at 4 months.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Endothelial function measured by the following at baseline, 2 and 4 months:

1. Laser Doppler flowmetry after iontophoretic delivery of acetylcholine and sodium nitroprusside (microvascular)
2. Brachial artery flow mediated dilatation (macrovascular)

Key secondary outcome(s)

The following were assessed at baseline, 2 and 4 months:

1. Endothelial function measured by blood testing of vascular function and damage (E selectin, thrombomodulin)
2. Arterial stiffness measured by ultrasound echo tracking and applanation tonometry
3. Oxidative stress (Isoprostane levels)
4. RA disease activity (28-item Disease Activity Score [DAS28], Health Assessment Questionnaire [HAQ], 36-item Short Form health survey [SF-36])

Completion date

25/04/2008

Eligibility**Key inclusion criteria**

1. Both males and females, 18 years old or over
2. Fulfil the 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis
3. No exposure to anti-TNFa drugs in the last 3 months
4. Fulfil the National Institute for Clinical Excellence guidelines on the use of anti-TNFa drugs in rheumatoid arthritis* and be:
 - 4.1. About to start etanercept or adalimumab (treatment group)
 - 4.2. About to start methotrexate (control group)

* The patients in the control group must have had adequate therapeutic trial of at least one previous Disease Modifying Anti-Rheumatic Drug (DMARD) rather than two

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Previous cardiovascular or cerebrovascular event in the last 3 years
2. Undergoing treatment for a cardiovascular risk factor except:
 - 2.1. Patients with hypertension on stable medication for the last 3 months
 - 2.2. Patients with hypercholesterolaemia on stable medication for the last 3 months

Date of first enrolment

10/02/2006

Date of final enrolment

25/04/2008

Locations**Countries of recruitment**

United Kingdom

Scotland

Study participating centre

Vascular and Inflammatory Diseases Research Unit

Dundee

United Kingdom

DD1 9SY

Sponsor information**Organisation**

University of Dundee (UK)

ROR

<https://ror.org/03h2bxq36>

Funder(s)

Funder type

Industry

Funder Name

Wyeth

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/03/2010 | | Yes | No |